These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 21984144)

  • 21. Role of imaging in the preoperative staging of small bowel neuroendocrine tumors.
    Chambers AJ; Pasieka JL; Dixon E; Rorstad O
    J Am Coll Surg; 2010 Nov; 211(5):620-7. PubMed ID: 21035044
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased Grade in Neuroendocrine Tumor Metastases Negatively Impacts Survival.
    Keck KJ; Choi A; Maxwell JE; Li G; O'Dorisio TM; Breheny P; Bellizzi AM; Howe JR
    Ann Surg Oncol; 2017 Aug; 24(8):2206-2212. PubMed ID: 28560597
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic Factors Associated With Progression for Advanced-Stage/G1 and G2 Small-Bowel Neuroendocrine Tumors After Multimodal Therapy: Experience From a Tertiary Referral Center.
    Khetan P; Oyewole F; Wolin E; Kim MK; Divino CM
    Pancreas; 2020 Apr; 49(4):509-513. PubMed ID: 32224719
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Indications and operative procedures for neuroendocrine liver metastases].
    Musholt TJ; Lang H
    Chirurg; 2009 Feb; 80(2):113-21. PubMed ID: 19212693
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Resection of the primary tumor improves survival in patients with gastro-entero-pancreatic neuroendocrine neoplasms with liver metastases: A SEER-based analysis.
    Zheng M; Li Y; Li T; Zhang L; Zhou L
    Cancer Med; 2019 Sep; 8(11):5128-5136. PubMed ID: 31328428
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Tumors of the lower gastrointestinal tract : Indication and extent of lymph node dissection].
    Merkel S; Weber K; Perrakis A; Göhl J; Hohenberger W
    Chirurg; 2010 Feb; 81(2):117-22; 124-26. PubMed ID: 20146049
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Upfront surgery of small intestinal neuroendocrine tumors. Time to reconsider?
    Daskalakis K; Tsolakis AV
    World J Gastroenterol; 2018 Aug; 24(29):3201-3203. PubMed ID: 30090001
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Update on Surgical Management of Small Bowel Neuroendocrine Tumors.
    Moris D; Ntanasis-Stathopoulos I; Tsilimigras DI; Vagios S; Karamitros A; Karaolanis G; Griniatsos J; Papalampros A; Papaconstantinou I; Glantzounis GK; Spartalis E; Blazer DG; Felekouras E
    Anticancer Res; 2018 Mar; 38(3):1267-1278. PubMed ID: 29491050
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases.
    Hellman P; Lundström T; Ohrvall U; Eriksson B; Skogseid B; Oberg K; Tiensuu Janson E; Akerström G
    World J Surg; 2002 Aug; 26(8):991-7. PubMed ID: 12016480
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Survival and disease recurrence in patients operated for small intestinal neuroendocrine tumors at a referral hospital.
    Folkestad O; Wasmuth HH; Mjønes P; Fougner R; Hauso Ø; Fossmark R
    Surg Oncol; 2020 Dec; 35():336-343. PubMed ID: 32979699
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk factors affecting prognosis in metachronous liver metastases from WHO classification G1 and G2 gastroenteropancreatic neuroendocrine tumors after initial R0 surgical resection.
    Lv Y; Han X; Xu XF; Ji Y; Zhou YH; Sun HC; Zhou J; Fan J; Lou WH; Huang C
    BMC Cancer; 2019 Apr; 19(1):335. PubMed ID: 30961559
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic Factors for Survival among Patients with Small Bowel Neuroendocrine Tumours Associated with Mesenteric Desmoplasia.
    Laskaratos FM; Diamantopoulos L; Walker M; Walton H; Khalifa M; El-Khouly F; Koffas A; Demetriou G; Caplin M; Toumpanakis C; Mandair D
    Neuroendocrinology; 2018; 106(4):366-380. PubMed ID: 29320779
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aggressive Locoregional Treatment Improves the Outcome of Liver Metastases from Grade 3 Gastroenteropancreatic Neuroendocrine Tumors.
    Du S; Ni J; Weng L; Ma F; Li S; Wang W; Sang X; Lu X; Zhong S; Mao Y
    Medicine (Baltimore); 2015 Aug; 94(34):e1429. PubMed ID: 26313798
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for a novel therapeutic target.
    Gamboa AC; Ethun CG; Postlewait LM; Lopez-Aguiar AG; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Kooby DA; Staley CA; Cardona K; Maithel SK
    Surg Oncol; 2020 Dec; 35():460-465. PubMed ID: 33080545
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IMP3 expression in small-intestine neuroendocrine neoplasms: a new predictor of recurrence.
    Massironi S; Del Gobbo A; Cavalcoli F; Fiori S; Conte D; Pellegrinelli A; Milione M; Ferrero S
    Endocrine; 2017 Nov; 58(2):360-367. PubMed ID: 28210937
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Pancreas as a Site of Metastasis or Second Primary in Patients with Small Bowel Neuroendocrine Tumors.
    Scott AT; Pelletier D; Maxwell JE; Sherman SK; Keck KJ; Li G; Dillon JS; O'Dorisio TM; Bellizzi AM; Howe JR
    Ann Surg Oncol; 2019 Aug; 26(8):2525-2532. PubMed ID: 31011904
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of Clinical Prognostic Factors and Further Delineation of the Effect of Mesenteric Fibrosis on Survival in Advanced Midgut Neuroendocrine Tumours.
    Laskaratos FM; Walker M; Wilkins D; Tuck A; Ramakrishnan S; Phillips E; Gertner J; Megapanou M; Papantoniou D; Shah R; Banks J; Vlachou E; Garcia-Hernandez J; Woodbridge L; Papadopoulou A; Grant L; Theocharidou E; Watkins J; Luong TV; Mandair D; Caplin M; Toumpanakis C
    Neuroendocrinology; 2018; 107(3):292-304. PubMed ID: 30153671
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Number, not size, of mesenteric tumor deposits affects prognosis of small intestinal well-differentiated neuroendocrine tumors.
    Gonzalez RS; Cates JMM; Shi C
    Mod Pathol; 2018 Oct; 31(10):1560-1566. PubMed ID: 29795438
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effective cytoreduction can be achieved in patients with numerous neuroendocrine tumor liver metastases (NETLMs).
    Scott AT; Breheny PJ; Keck KJ; Bellizzi AM; Dillon JS; O'Dorisio TM; Howe JR
    Surgery; 2019 Jan; 165(1):166-175. PubMed ID: 30343949
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Surgical treatment of neuroendocrine tumors in the second portion of the duodenum: a single center experience and systematic review of the literature.
    Iwasaki T; Nara S; Kishi Y; Esaki M; Shimada K; Hiraoka N
    Langenbecks Arch Surg; 2017 Sep; 402(6):925-933. PubMed ID: 27915372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.